Migraine is a complex condition when considered from the perspective of its pathophysiology. Moreover, it is highly prevalent and of priority interest in public health. Gepants are a highly-effective and specific therapeutic option, although their recent arrival in Latin America raises particular questions and expectations. A narrative review of the four medications available outside Latin America at this time is provided and the main considerations that should be borne in mind before and during their adoption are presented. Appropriate patient selection and marketing cost will be key determinants for their consolidation as an alternative to traditional medications used in migraine.